Results 171 to 180 of about 33,780 (265)

Reader reception of translation strategies for Li Bai's "Yu Jie Yuan": Empirical evidence from a mixed-methods study. [PDF]

PLoS One
Chang H, Zhao J, Sun Y, Ding H.
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Towards a resource for multilingual lexicons: an MT assisted and human-in-the-loop multilingual parallel corpus with multi-word expression annotation. [PDF]

Lang Resour Eval
Han L, Mohamed NH, Rassem M, Jones GJF, Smeaton AF, Nenadic G.   +5 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

The ROBOKOP v1.0 knowledge graph system for exploring relationships between biomedical entities. [PDF]

Sci Rep
Fecho K, Morris E, Beasley JM, Carter EK, Chung CH, Edwards S, Glymph D, Korn D, Olasunkanmi O, Pasfield C, Ramon M, Richardson J, Tucker N, Williams D, Zheng W, Tropsha A, Bizon C.   +16 more
europepmc   +1 more source

DNA methylation and expression of MAPRE3 affect overall survival of early‐stage non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
Both cg12821679MAPRE3 methylation and MAPRE3 expression are significantly associated with overall survival (OS) of non‐small cell lung cancer. Meanwhile, MAPRE3 expression significantly modified the effect of smoking cessation on OS. Smoking cessation benefits OS merely for patients with high MAPRE3 expression.
Chao Chen, Jiancheng Cheng, Ruili Hou, Xiaoyuan Zheng, Li Su, Maria Moksnes Bjaanæs, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, David C. Christiani, Feng Chen, Xiaofei Cao, Ruyang Zhang   +14 more
wiley   +1 more source

A family like this. [PDF]

CMAJ
Cheng A.
europepmc   +1 more source

Clinical performance of the urine‐based TERT promoter AbsoluteQ Digital PCR for non‐invasive detection of bladder cancer

Molecular Oncology, EarlyView.
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel, Izabela Kubiak, Lena Rutkowska, Żaneta Kasprzyk, Łukasz Kępczyński, Michał Bednarek, Dariusz Sobieraj, Jacek Wilkosz, Piotr Kania, Adam Jędrzejczyk, Bogdan Kałużewski, Agnieszka Gach, Tadeusz Kałużewski   +12 more
wiley   +1 more source

Announcing the Biomedical Data Translator: Initial Public Release. [PDF]

Clin Transl Sci
Fecho K, Glusman G, Baranzini SE, Bizon C, Brush M, Byrd W, Chung L, Crouse A, Deutsch E, Dumontier M, Foksinska A, Hadlock J, He K, Huang S, Hubal R, Hyde GM, Israni S, Kenmogne K, Koslicki D, Marcette JD, Mathe EA, Mesbah A, Moxon SAT, Mungall CJ, Osborne J, Pasfield C, Qin G, Ramsey SA, Reese J, Roach JC, Rose R, Soman K, Su AI, Ta C, Vaidya G, Weber R, Wei Q, Williams M, Wu C, Xu C, Yakaboski C, Biomedical Data Translator Consortium.   +41 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source